CAR T-Cell Therapy Market Predicted to Reach USD 6.1 Billion by 2030 at 13.5% CAGR: Allied Market Research

Portland, OR, Sept. 05, 2022 (GLOBE NEWSWIRE) — Allied Market Research published a report, titled, “CAR T-Cell Therapy Market by Drug type (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Others), by Indication (Lymphoma, Acute Lymphocytic Leukemia, Others), by End user (Hospitals, Cancer Treatment Centers): Global Opportunity Analysis and Industry Forecast, 2021-2031.” According to the report, the global CAR T-cell therapy industry generated $1.7 billion in 2021, and is expected to reach $6.1 billion by 2031, witnessing a CAGR of 13.5% from 2022 to 2031.

Drivers, Restraints, and Opportunities

Increase in demand for ideal therapeutics for cancer treatment, rise in prevalence of cancer, supportive reimbursement policies in some countries related to CAR T-cell therapy medicine, and surge in awareness of CAR T-cell therapy medicines drive the growth of the global CAR T-cell therapy market. However, lack of skilled professionals for CAR T-cell therapy and high cost of therapy hinder the market growth. On the other hand, rise in approval of new medicine of CAR T-cell therapy and drugs present new opportunities in the coming years.

Download Sample Report- https://www.alliedmarketresearch.com/request-sample/17358

Impact of Covid-19 on CAR T-Cell Therapy Market-

• The number of CAR T-cell therapies reduced considerably during the Covid-19 pandemic, due to shift of resources toward treatment of increasing Covid-infected patients. Governments of many countries released guidelines that postponed the non-elective surgeries.
• Discovery and development activities of CAR T-cell therapy medicine slowed down significantly. The decrease in number of clinical trials impacted the CAR T-cell therapy market size.
• Supply chain disruptions due to lockdown measures and ban on import-export activities created a supply-demand gap. This, in turn, impacted the overall market revenue.
• Post-pandemic, the development activities of CAR T-cell therapy medicine are expected to increase with rise in R&D activities, rapidly expanding clinical trial activities, and commercialization.

Get detailed COVID-19 impact analysis on the Car T-cell Therapy Market- https://www.alliedmarketresearch.com/request-for-customization/17358?reqfor=covid

The lymphoma segment to maintain its leadership status during the forecast period

Based on indication, the lymphoma segment accounted for the highest market share in 2021, contributing to more than half of the global CAR T-cell therapy market, and is projected to maintain its leadership status during the forecast period. This is attributed to high number of approved CAR T-cell therapeutics for treatment of different forms of lymphoma. However, the acute lymphocytic leukemia segment is estimated to witness the highest CAGR of 14.5% from 2022 to 2031. This is due to increase in awareness of CAR T-cell therapeutics for treatment of acute lymphocytic leukemia and launch of novel drugs.

The hospitals segment to maintain its lead position during the forecast period

Based on end user, the hospitals segment contributed to the highest market share in 2021, holding nearly three-fifths of the global CAR T-cell therapy market, and is projected to maintain its lead position during the forecast period. This is attributed to well-equipped operation theatre and high purchasing power. However, the cancer treatment centers segment is estimated to register the highest CAGR of 14.1% from 2022 to 2031, owing to availability of a wide range of treatment choices and increase in a

Based on drug type, the axicabtagene ciloleucel segment held the largest market share in 2021, accounting for around two-fifths of the global CAR T-cell therapy market, and is expected to maintain its dominant share during the forecast period. This is due to increase in adoption of axicabtagene ciloleucel for treatment of relapsed or refractory large B-cell lymphoma and relapsed or refractory follicular lymphoma. However, the brexucabtagene autoleucel segment is projected to grow at the highest CAGR of 15.9% from 2022 to 2031, owing to rise in approval of CAR T-cell therapies in different countries for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

For Purchase Inquiry- https://www.alliedmarketresearch.com/purchase-enquiry/17358

North America to maintain its lead status by 2031

Based on region, North America held the largest market share in 2021, accounting for nearly two-thirds of the global CAR T-cell therapy market, and is expected to maintain its lead status by 2031. This is due to the presence of key players and availability of approved therapeutics with high adoption of CAR T-cell therapies. However, Asia-Pacific is projected to manifest the fastest CAGR of 15.8% during the forecast period. This is due to rise in awareness regarding CAR T-cell therapy, the launch of new CART drugs, and rise in the number of target population.

Key Market Players

• Autolus
• Bluebird Bio-Inc.
• Bristol-Myers Squibb
• Caribou Biosciences Inc.
• Cartesian Therapeutics
• Celgene Corporation
• Cellectis
• Celyad, Gilead Sciences, Inc. (Kite Pharma Inc.)
• Intellia Therapeutics
• Juno Therapeutics
• Merck & Co. Inc.
• Miltenyi Biotech
• Novartis AG
• Pfizer Inc.
• Sorrento Therapeutics, Inc.

Official Press Release- https://www.alliedmarketresearch.com/press-release/car-t-cell-therapy-market.html

Similar Research Reports for Information, Communication and Technology:

 Europe In Vitro Fertilization (IVF) Market- Global Opportunity Analysis and Industry Forecast, 2021–2030

Neurovascular Devices Market- Global Opportunity Analysis and Industry Forecast, 2021–2030

Viral Vector and Plasmid DNA Manufacturing Market- Global Opportunity Analysis and Industry Forecast, 2021–2030

Gene Therapy Market- Global Opportunity Analysis and Industry Forecast, 2021–2030

Radiodermatitis Market- Global Opportunity Analysis and Industry Forecast, 2021–2030

                                                                            
AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model):

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
[email protected] 
Web: https://www.alliedmarketresearch.com